Novamind reports that four health insurers are now covering its ketamine treatment for Treatment-Resistant Depression.
Novamind reports that four health insurers are now covering its ketamine treatment for Treatment-Resistant Depression.
Compass Pathways reports successful results from its Phase IIb clinical trial of COMP360 for the treatment of Treatment Resistant Depression (TRD).
CYB003 is demonstrating superior treatment properties vs. an oral dosage of psilocybin.
Novamind reports its full year results for fiscal 2021, including industry-leading revenue of CAD$6 million.
Cybin announces receiving its DEA Schedule I Manufacting License, necessary to work with Schedule I controlled substances in the U.S.
Bright Minds Biosciences announces it has uplisted to the NASDAQ, trading under the symbol "DRUG".
Red Light Holland appoints a new Chief Financial Officer, David Ascott.
MINDCURE announces an LOI with Awaken Life Sciences for the deployment of MINDCURE's iSTRYM digital therapeutics platform in Awaken's addiction treatment clinics.
MINDCURE announces its Q1 fiscal 2022 results, including initial release of its iSTRYM platform. Cash and equivalents of CAD$15.6 million as of August 31, 2021.
MindMed announces a new R&D initiative focused on an MDMA derivative, and aimed at treating social anxiety.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now